Pictet Asset Management Holding SA raised its holdings in Medline (NASDAQ:MDLN – Free Report) by 21.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 215,114 shares of the company’s stock after buying an additional 37,928 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Medline were worth $7,464,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in shares of Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after acquiring an additional 254 shares during the last quarter. Covestor Ltd raised its position in shares of Medline by 31.8% in the 3rd quarter. Covestor Ltd now owns 1,953 shares of the company’s stock valued at $68,000 after purchasing an additional 471 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of Medline by 100.0% in the 2nd quarter. NewEdge Advisors LLC now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 475 shares during the last quarter. Allworth Financial LP boosted its stake in Medline by 86.2% in the 2nd quarter. Allworth Financial LP now owns 1,052 shares of the company’s stock worth $41,000 after purchasing an additional 487 shares in the last quarter. Finally, Reyes Financial Architecture Inc. acquired a new stake in Medline in the 3rd quarter worth approximately $30,000.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. Barclays cut their price target on shares of Medline from $45.00 to $43.00 and set an “overweight” rating on the stock in a research note on Friday, October 9th. Weiss Ratings raised shares of Medline from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, November 9th. Truist Financial lowered their price objective on shares of Medline from $56.00 to $47.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Evercore set a $39.00 price objective on shares of Medline in a research note on Thursday, August 6th. Finally, William Blair reissued an “outperform” rating on shares of Medline in a report on Wednesday, September 23rd. Twenty-three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $46.08.
Get Our Latest Stock Report on MDLN
Medline Stock Performance
Shares of NASDAQ:MDLN opened at $39.47 on Monday. Medline has a 52-week low of $31.37 and a 52-week high of $50.88. The stock has a market cap of $51.92 billion and a price-to-earnings ratio of 89.71. The company has a quick ratio of 2.51, a current ratio of 4.04 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $35.28 and a 200-day moving average price of $39.37.
Medline (NASDAQ:MDLN – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The firm had revenue of $7.86 billion during the quarter. Medline had a return on equity of 8.21% and a net margin of 1.84%. Equities analysts predict that Medline will post 1.58 EPS for the current year.
Insider Transactions at Medline
In other Medline news, major shareholder Private Ltd Gic sold 2,570,999 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the completion of the transaction, the insider directly owned 20,231,483 shares of the company’s stock, valued at approximately $715,182,924.05. This trade represents a 11.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 6,348,676 shares of company stock worth $224,525,137. Company insiders own 0.81% of the company’s stock.
Medline Company Profile
Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations. The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations. Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.
Read More
- Five stocks we like better than Medline
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MDLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medline (NASDAQ:MDLN – Free Report).
Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.
